CN100502916C - 一种抗病毒的药物组合物及其制备方法 - Google Patents
一种抗病毒的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN100502916C CN100502916C CNB2006100815188A CN200610081518A CN100502916C CN 100502916 C CN100502916 C CN 100502916C CN B2006100815188 A CNB2006100815188 A CN B2006100815188A CN 200610081518 A CN200610081518 A CN 200610081518A CN 100502916 C CN100502916 C CN 100502916C
- Authority
- CN
- China
- Prior art keywords
- powder
- add
- weight portions
- radix
- radix scutellariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 230000002155 anti-virotic effect Effects 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 123
- 239000003814 drug Substances 0.000 claims abstract description 88
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 238000001291 vacuum drying Methods 0.000 claims abstract description 24
- 238000009835 boiling Methods 0.000 claims abstract description 12
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 33
- 239000006071 cream Substances 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 26
- 241000196133 Dryopteris Species 0.000 claims description 25
- 241000628997 Flos Species 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 239000006228 supernatant Substances 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 238000007796 conventional method Methods 0.000 claims description 11
- 230000006837 decompression Effects 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 11
- 238000001556 precipitation Methods 0.000 claims description 11
- 238000004064 recycling Methods 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000890 drug combination Substances 0.000 claims description 3
- XGFJCRNRWOXGQM-UHFFFAOYSA-N hot-2 Chemical compound CCSC1=CC(OC)=C(CCNO)C=C1OC XGFJCRNRWOXGQM-UHFFFAOYSA-N 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 24
- 241000894006 Bacteria Species 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 4
- 238000001914 filtration Methods 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 241000050051 Chelone glabra Species 0.000 abstract 2
- 240000005373 Panax quinquefolius Species 0.000 abstract 2
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 241000431991 Aglaomorpha quercifolia Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 48
- 239000003795 chemical substances by application Substances 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 34
- 210000002966 serum Anatomy 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 30
- 239000007788 liquid Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 19
- 230000037396 body weight Effects 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000010790 dilution Methods 0.000 description 13
- 239000012895 dilution Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 206010022000 influenza Diseases 0.000 description 12
- 241000711573 Coronaviridae Species 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 241000712461 unidentified influenza virus Species 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 9
- 235000010603 pastilles Nutrition 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000029052 metamorphosis Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 231100001274 therapeutic index Toxicity 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000003228 hemolysin Substances 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000000436 anus Anatomy 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012109 statistical procedure Methods 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 231100000645 Reed–Muench method Toxicity 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 231100000028 nontoxic concentration Toxicity 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 231100000816 toxic dose Toxicity 0.000 description 4
- 208000031636 Body Temperature Changes Diseases 0.000 description 3
- 241000167880 Hirundinidae Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000001698 pyrogenic effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001524 infective effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004279 orbit Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 229940100050 virazole Drugs 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 231100001134 median toxic concentration Toxicity 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100815188A CN100502916C (zh) | 2006-05-25 | 2006-05-25 | 一种抗病毒的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100815188A CN100502916C (zh) | 2006-05-25 | 2006-05-25 | 一种抗病毒的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101077380A CN101077380A (zh) | 2007-11-28 |
CN100502916C true CN100502916C (zh) | 2009-06-24 |
Family
ID=38905151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100815188A Active CN100502916C (zh) | 2006-05-25 | 2006-05-25 | 一种抗病毒的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100502916C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101947297A (zh) * | 2010-09-17 | 2011-01-19 | 北京中医药大学东直门医院 | 一种治疗老年肺炎的中药组合物、免煎颗粒剂及其制备方法 |
CN104111295A (zh) * | 2014-07-24 | 2014-10-22 | 神威药业集团有限公司 | 一种中药制剂的质量控制方法 |
CN111632116A (zh) * | 2020-06-17 | 2020-09-08 | 上海凯宝药业股份有限公司 | 一种抗病毒性感冒中药制剂的制备方法 |
CN115089652A (zh) * | 2022-06-14 | 2022-09-23 | 深圳市中医院 | 清肺固本汤的中药方剂及其制备方法 |
-
2006
- 2006-05-25 CN CNB2006100815188A patent/CN100502916C/zh active Active
Non-Patent Citations (2)
Title |
---|
中药抗流感病毒研究概况. 李艳华等.中国兽医杂志,第39卷第6期. 2003 |
中药抗流感病毒研究概况. 李艳华等.中国兽医杂志,第39卷第6期. 2003 * |
Also Published As
Publication number | Publication date |
---|---|
CN101077380A (zh) | 2007-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101953985A (zh) | 一种具有清肺止咳作用的药物 | |
CN100348258C (zh) | 一种治疗上呼吸道感染的药物及其制备方法 | |
CN101628108B (zh) | 治疗外感风寒的中药颗粒剂及其制备方法 | |
CN100502916C (zh) | 一种抗病毒的药物组合物及其制备方法 | |
CN103977314A (zh) | 一种治疗呼吸道疾病的药物组合物及制备方法和用途 | |
CN101757565B (zh) | 一种治疗小儿急性支气管炎的中药组合物及制备方法 | |
CN101773580B (zh) | 一种用于治疗小儿急性支气管炎的中药组合物及制备方法 | |
CN101618146A (zh) | 一种用于治疗上呼吸道感染的复方中药制剂及其制备方法 | |
CN103316086A (zh) | 一种治疗流行性感冒的藏药及其制备方法 | |
CN100531757C (zh) | 一种治疗风热型感冒的药物组合物及其制备方法 | |
CN102526209B (zh) | 一种中药固体制剂(剂型) | |
CN102526236A (zh) | 一种治疗流行性感冒的药物及其制备方法 | |
CN106138932A (zh) | 用于治疗小儿哮喘的中药 | |
CN102068479B (zh) | 治疗慢性***的中药组合物及其制备方法 | |
CN104707126A (zh) | 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 | |
CN101485757B (zh) | 一种治疗小儿外感发热的中药组合物及其制备方法 | |
CN101843612B (zh) | 异荭草苷作为制备抗呼吸道合胞病毒的药物的用途 | |
CN100546605C (zh) | 一种治疗病毒性上呼吸道感染的药物组合物及其制备方法 | |
CN102319321B (zh) | 一种治疗慢性乙型肝炎的中药组合物及其制备方法和应用 | |
CN102178757B (zh) | 一种原料含有发酵虫草菌粉和梨的药物组合物 | |
CN101816721B (zh) | 一种治疗小儿外感发热的中药组合物及其制备方法 | |
CN102579596B (zh) | 一种中药固体制剂及其制法(处方) | |
CN104998078A (zh) | 一种用于治疗感染性心内膜炎的中药 | |
CN105079486A (zh) | 一种治疗慢性胃炎的药剂 | |
CN104398965A (zh) | 一种用于治疗病毒性感冒的中药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHINEWAY PHARMACEUTICAL GROUP LIMITED Free format text: FORMER OWNER: CAO HONGXIN Effective date: 20140410 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100700 DONGCHENG DISTRICTK, BEIJING TO: 051430 SHIJIAZHUANG, HEBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140410 Address after: Hebei province Luancheng County South 051430 Patentee after: China Shineway Pharmaceutical Group Co., Ltd. Address before: 100700 Beijing city Dongzhimen Nanxiaojie No. 16 Patentee before: Cao Hongxin |